Public funding for research on antibacterial resistance in the JPIAMR countries, the European Commission, and related European Union agencies: a systematic observational analysis.
Public funding for research on antibacterial resistance in the JPIAMR countries, the European Commission, and related European Union agencies: a systematic observational analysis.
复制标题
DOI：
10.1016/s1473-3099(15)00350-3
复制
发表时间：
2016-04
期刊：
影响因子：
--
通讯作者：
Goossens H
中科院分区：
文献类型：
--
作者：
Kelly R;Zoubiane G;Walsh D;Ward R;Goossens H
抗菌素耐药性感染持续上升，导致全球发病率和死亡率上升。由于没有新的抗生素类别进入市场，而且有可能回到抗生素之前的时代，因此设立了关于抗菌素耐药性的联合规划倡议(JPIAMR)来解决这一问题。我们的目标是量化JPIAMR国家和欧盟(EU)层面上公共资助的抗菌素耐药性研究的规模和范围，以确定差距和未来的机会。我们进行了一项系统的观察性分析，检查了抗菌药物耐药性研究资金。从2007年1月1日到2013年12月31日，系统地搜索了19个国家和欧盟层面的资助组织的数据库，以寻找公共资助的抗菌素耐药性研究。我们根据JPIAMR战略研究议程的六个优先主题(治疗学、诊断学、监测、传播、环境和干预)对研究进行分类，并进行观察性分析。只收集了由公共资助机构资助的研究，没有联系私人机构进行投资。基础研究、应用研究和临床研究的项目，包括流行病学、公共卫生和兽医研究和试验，通过组织的关键字搜索确定，纳入标准基于JPIAMR战略研究议程的六个优先主题，使用项目标题和摘要作为过滤器。我们确定了1243个抗菌素耐药性研究项目，在19个国家和欧盟层面的公共投资总额为13亿欧元，其中包括对创新药物倡议的公共投资。在这段时间内用于抗菌药耐药性研究的总金额中，国家层面的投资为6.466亿欧元(49.5%)，欧盟层面的投资为6.592亿欧元(50.5%)。当按六个优先专题对项目进行分类时，我们发现，在国家一级资助的1208个项目中，有763个(63%)属于治疗领域，而传播学领域为185个(15%)，诊断学领域为131个(11%)，干预领域为53个(4%)，环境领域仅为37个(3%)，监测领域为39个(3%)。这是第一次对这种规模和范围的抗菌药耐药性研究资金进行系统分析，这取决于包括在内的组织的数据的可用性和准确性。在项目数量和相关投资以及六个优先专题方面，各国之间的差异很大。为了确定JPIAMR国家的未来方向，需要对整个欧洲和加拿大的资金状况有一个清晰的了解。各国应共同努力，通过加强国家和国际协调与合作，协调研究活动，并共同汇集资源，为多学科项目提供资金，从而提高研究资金的效果。JPIAMR已经开发了一个公开可用的数据库，以记录收集到的抗菌素耐药性研究，并可用作分析2014年起资助情况的基线。JPIAMR和欧盟委员会。
Antibacterial resistant infections are rising continuously, resulting in increased morbidity and mortality worldwide. With no new antibiotic classes entering the market and the possibility of returning to the pre-antibiotic era, the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) was established to address this problem. We aimed to quantify the scale and scope of publicly funded antibacterial resistance research across JPIAMR countries and at the European Union (EU) level to identify gaps and future opportunities. We did a systematic observational analysis examining antibacterial resistance research funding. Databases of funding organisations across 19 countries and at EU level were systematically searched for publicly funded antibacterial resistance research from Jan 1, 2007, to Dec 31, 2013. We categorised studies on the basis of the JPIAMR strategic research agenda's six priority topics (therapeutics, diagnostics, surveillance, transmission, environment, and interventions) and did an observational analysis. Only research funded by public funding bodies was collected and no private organisations were contacted for their investments. Projects in basic, applied, and clinical research, including epidemiological, public health, and veterinary research and trials were identified using keyword searches by organisations, and inclusion criteria were based on the JPIAMR strategic research agenda's six priority topics, using project titles and abstracts as filters. We identified 1243 antibacterial resistance research projects, with a total public investment of €1·3 billion across 19 countries and at EU level, including public investment in the Innovative Medicines Initiative. Of the total amount invested in antibacterial resistance research across the time period, €646·6 million (49·5%) was invested at the national level and €659·2 million (50·5%) at the EU level. When projects were classified under the six priority topics we found that 763 (63%) of 1208 projects funded at national level were within the area of therapeutics, versus 185 (15%) in transmission, 131 (11%) in diagnostics, 53 (4%) in interventions, and only 37 (3%) in environment and 39 (3%) in surveillance. This was the first systematic analysis of research funding of antibacterial resistance of this scale and scope, which relied on the availability and accuracy of data from organisations included. Large variation was seen between countries both in terms of number of projects and associated investment and across the six priority topics. To determine the future direction of JPIAMR countries a clear picture of the funding landscape across Europe and Canada is needed. Countries should work together to increase the effect of research funding by strengthening national and international coordination and collaborations, harmonising research activities, and collectively pooling resources to fund multidisciplinary projects. The JPIAMR have developed a publicly available database to document the antibacterial resistance research collected and can be used as a baseline to analyse funding from 2014 onwards. JPIAMR and the European Commission.